Extremely bearish after a 161% jump on successful clinical trial results. Falling action predicates a new high low point for the stock and further stabilization going forward
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
